Management

Anthony Ley, Chief Executive Officer
Anthony Ley is the Chief Executive Officer of CollabRx. He previously served as President and CEO of Harmonic Inc. from 1988 until 2006. At Harmonic, a leading provider of digital video, broadband optical networking, and IP delivery systems, Mr. Ley was elected Chairman of the Board of Directors in 1995. He led Harmonic’s growth and development for 18 years. After retiring from active service with the company, he continues to serve as the non-executive Chairman of the Board of Directors. From 1963 to 1987, Mr. Ley was employed at Schlumberger, both in Europe and the United States, holding various senior business management and research and development positions, most recently as Vice President, Research and Engineering at Fairchild Semiconductor/Schlumberger in Palo Alto, California. Mr. Ley holds an M.A. in Mechanical Sciences from the University of Cambridge and an S.M.E.E. from the Massachusetts Institute of Technology, is named as an inventor on 29 patents and is a Fellow of the I.E.E. (U.K.) and a senior member of the I.E.E.E.

Jay M. Tenenbaum, Ph.D., Chairman and Chief Scientist
Jay M. (“Marty”) Tenenbaum is the founding visionary and Chairman of CollabRx. A world-renowned Internet commerce pioneer and visionary, Dr. Tenenbaum founded CommerceNet in 1994 to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. When Commerce One acquired Veo Systems in January 1999, Dr. Tenenbaum became Chief Scientist and was instrumental in shaping the company’s business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Currently, his focus is on transforming healthcare and accelerating therapy development through collaborative e-science. Prior to CommerceNet, he was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), a secure Web transaction (1993) and Internet auction (1993). Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon’s new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

Jonathan Jacoby, Chief Operating Officer
Jonathan Jacoby is the Chief Operating Officer of CollabRx. He has worked as an organizational entrepreneur, executive, and strategic planning consultant for nonprofit organizations. Mr. Jacoby was co-founder and former CEO of the Hide & Seek Foundation for Lysosomal Disease Research, a non-profit foundation created by parents, scientists, business leaders, and philanthropists. As the chief staff person of the foundation, he worked to accelerate medical research and scientific innovation. He also previously founded and served as Executive Director of Israel Policy Forum, a bipartisan advocacy group and think tank, and of New Israel Fund, a philanthropic foundation. He also served as a partner at the consulting firm Bronznick Jacoby, LLC, working with not-for-profit organizations to launch new ventures and programs, position organizations for growth, and guide agencies through periods of transition. Mr. Jacoby holds an M.E. from Harvard University, a B.A. from UCLA, and a B.Lit from the University of Judaism.

John G. Curd, M.D., Consulting Chief Medical Officer
John Curd has been the President and Chief Medical Officer at Threshold Pharmaceuticals since 2007. He had joined Threshold Pharmaceuticals as a member of the management team to lead the clinical development of product development candidates including Threshold's hypoxia activated prodrug, TH-302. Prior to Threshold Pharmaceuticals, Dr. Curd was President and Chief Medical Officer at Novacea, Inc. since 2001. He had served in senior roles at Maxygen and VaxGen, Inc. from June 1999 to December 2001, and Vice President of Clinical Development at Genentech, Inc. from December 1991 to June 1999. While at Genentech, he directed the clinical development of Herceptin®, Rituxan®, Xolair®, and Raptiva®. From 1978 to 1991, Dr. Curd served in various positions including President of the Medical Staff at Scripps Clinical and Research Foundation in La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.

Jeff Shrager, Ph.D., Chief Technology Officer
Jeff Shrager is the CTO of CollabRx, and a consulting associate professor in the Symbolic Systems program at Stanford University. As a computational psychologist of science, Dr. Shrager seeks to understand how science works, and to build human-computer networks that facilitate discovery. Previously, Dr. Shrager co-founded several scientific-computing start-ups (including Afferent Systems, acquired by MDL), and invented BioBike, a web-based biological knowledge platform enabling biologists to develop, run, and share complex analyses of genomic information. Dr. Shrager holds degrees in computer science and cognitive neuroscience from The University of Pennsylvania and CMU, and publishes extensively in scientific computing, AI, biology, genomics, and the cognitive sciences.

Aytek Çelik, Vice President, Marketing
Aytek Çelik is the Vice President of Marketing at CollabRx. Previously, Ms. Çelik worked as a consulting entrepreneur at CommerceNet focused on solving problems in health care and medical research by applying Web 2.0 communication tools and collective intelligence. Prior to CommerceNet, Ms. Çelik worked at Yahoo from 2001 to 2006, most recently as Senior Manager for Local Search and Local Advertising products. She has also founded an Internet Appliance startup backed by consumer electronics firm Vestel, and in an earlier position at Vestel, she led the international purchasing and logistics division. Ms. Çelik holds a Bachelor’s degree in Economics from Yale University and a certificate from the Kyoto Center for Japanese Studies.

Raphael Lehrer, Ph.D., Vice President, New Business Development
Raphael Lehrer is the Vice President for New Business Development at CollabRx. Previously, Dr. Lehrer was the Executive Director of Strategic Alliances for Gene Logic's Drug Repositioning and Selection Business where he negotiated alliances with pharmaceutical companies to discover new therapeutic uses for their compounds that have failed in late-stage clinical trials. In earlier positions at Gene Logic, he played a key role in formulating strategy for the company; evaluating, acquiring, and integrating the preclinical CRO business; and in adding service-based offerings to Gene Logic's toxicogenomics business. Prior to joining Gene Logic, Dr. Lehrer worked at The Boston Consulting Group, where he supported top-ten pharmaceutical clients on a variety of R&D and commercial issues, including formulating licensing strategies, clinical development process design, regulatory processes, post-merger integration, and outsourcing strategies. Additionally, Dr. Lehrer was a key contributor to BCG's positioning paper on the impact of genomics on pharmaceutical R&D. Dr. Lehrer holds a B.S. degree in Physics from Yale University and a Ph.D. degree in Physics from Harvard University, where he was awarded the Maurice Goldhaber Prize for best theoretical physics student.

Kai Mildenberger, Vice President, Operations
Kai Mildenberger is the Vice President for Operations at CollabRx. Most recently he co-founded and lead SupplyFrame as CEO from conception through launch and institutional funding. After conceiving and beginning SupplyFrame with backing from the CommerceNet Consortuim in 2002, Mr. Mildenberger built the company to support over 116 marketplaces, exceeding 8,000 users across over 4,500 companies. Prior to SupplyFrame, he led all operational business functions as COO of eConnections. Before eConnections, he was GM and CTO at Access360, a provider of policy-based provisioning products and services. Access360 was acquired by IBM's Tivoli unit in 2002 where the product lives on as TIM (Tivoli Identity Manager). Mr. Mildenberger managed the engineering of PeopleMover as its CTO from 1999 to 2000, and was instrumental in merging it with Opus360 Corp. and its IPO. Mr. Mildenberger began his career in 1991 when he founded IDEA Software & Consulting GmbH, which he sold to Computer Associates in 1996 to found the MK Group (later InterBiz) inside CA, combining all of the company’s business applications under one business unit.

Catherine Ley, Ph.D., Virtual Biotech Manager
Catherine Ley is a Virtual Biotech Manager at CollabRx. As a principal at Caradon Consulting, Dr. Ley has provided epidemiologic expertise and clinical research consulting to both non-profit and for-profit organizations. Previously a senior scientist and epidemiologist at the Institute for OneWorld Health, she was involved in the development of paromomycin for visceral leishmaniasis, which was approved in India in 2006. Prior positions have included work in both Africa and Latin America. Dr. Ley's interests have revolved primarily around global health and infectious diseases, particularly the causes of cancer. She holds a Ph.D. in epidemiology from the University of California, Berkeley, and both a M.S. and a B.S. in Biological Sciences from Stanford University..

Smruti Vidwans, Ph.D., Virtual Biotech Manager
Smruti Vidwans is a Virtual Biotech Manager at CollabRx. Dr. Vidwans brings extensive industry and academic experience in R&D strategy, early stage drug discovery, business development, and strategy and program management. She has consulted with a wide range of pharmaceutical companies, including Pfizer, GlaxoSmithKline, Roche Biosciences, Wyeth, Schering-Plough, on business strategy development, implementation and change management. She worked with McKinsey & Company where she was a key contributor to their Healthcare practice. She has also consulted with non-profits including the Institute for OneWorld Health and several startups in the drug discovery space. Dr. Vidwans was adjudged amongst the top 100 young investigators under 35 for her work on Tuberculosis drug discovery. She holds a Ph.D. in Genetics and Developmental Biology from the University of California, San Francisco, and an S.B. in Biology from the Massachusetts Institute of Technology.

Jay M. Tenenbaum, Ph.D., Chairman and Chief Scientist
Jay M. (“Marty”) Tenenbaum is the founding visionary and Chairman of CollabRx. A world-renowned Internet commerce pioneer and visionary, Dr. Tenenbaum founded CommerceNet in 1994 to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. When Commerce One acquired Veo Systems in January 1999, Dr. Tenenbaum became Chief Scientist and was instrumental in shaping the company’s business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Currently, his focus is on transforming healthcare and accelerating therapy development through collaborative e-science. Prior to CommerceNet, he was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), a secure Web transaction (1993) and Internet auction (1993). Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon’s new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

Anthony Ley, Chief Executive Officer
Anthony Ley is the Chief Executive Officer of CollabRx. He previously served as President and CEO of Harmonic Inc. from 1988 until 2006. At Harmonic, a leading provider of digital video, broadband optical networking, and IP delivery systems, Mr. Ley was elected Chairman of the Board of Directors in 1995. After retiring from active service with the company, he continues to serve as the non-executive Chairman of the Board of Directors. From 1963 to 1987, Mr. Ley was employed at Schlumberger, both in Europe and the United States, holding various senior business management and research and development positions, most recently as Vice President, Research and Engineering at Fairchild Semiconductor/Schlumberger in Palo Alto, California. Mr. Ley holds an M.A. in Mechanical Sciences from the University of Cambridge and an S.M.E.E. from the Massachusetts Institute of Technology, is named as an inventor on 29 patents and is a Fellow of the I.E.E. (U.K.) and a senior member of the I.E.E.E.

Rob Rodin, Director
Rob Rodin is the Chairman and CEO of RDN Group; strategic advisors focused on corporate transitions, customer interface, sales and marketing, distribution and supply chain management. (Customers include: GM, GE, US Navy, Avnet, Siemens, Simon and Schuster). Additionally, he serves as Vice Chairman, Executive Director and Chairman of the Investment Committee of CommerceNet which researches and funds open platform, interoperable business services to advance commerce. Mr. Rodin served for over 10 years as CEO and President of Marshall Industries (NYSE: MI) a global, industrial, electronics distributor and supply chain management company with over $2 billion in sales. Information Week Magazine highlighted Marshall Industries as the "World's Number One Company in the Use of Technology", and CIO Magazine recognized Mr. Rodin as one of the "Top 100 Leaders for the New Millennium". UCLA presented Mr. Rodin with the "Information Systems Award for System Leadership" and the University of Connecticut presented him with the "Distinguished Alumni Award" and elected him to the "University Hall of Fame". Mr. Rodin's best selling book, "Free, Perfect and Now: Connecting to the Three Insatiable Customer Demands", chronicles the radical transformation of Marshall Industries. The changes he led have been taught as case studies at Harvard Business School, Columbia University, USC, MIT, and Stanford University. Mr. Rodin’s Board activities include: the Board of Directors of Napster (NAPS)(formally Roxio) as Chairman of the Compensation Committee and a Member of the Audit Committee, Vice Chairman of the Board of Directors of CommerceNet, Board Member / Director of supplyFX, Board Member / Director of ALS Therapy Development Institute, Board Member / Director and Member of the Governance and Nominating Committee of SM&A (NASDQ: WINS), Director of Inter-tel (NASDAQ: INTL), Advisory Board of LASEC (Los Angeles Sports and Entertainment Commission), Advisory Board of Electronics Supply & Manufacturing Magazine (CMP Publications), on the planning committee for Harvard and Stanford Presidents Seminars (YPO) and on University of Connecticut's School of Business Board of Advisors (Executive Council and Strategic Development Committee) as well as several private company advisory boards. Mr. Rodin formerly served on the Advisory Board of Distribution at USC, the Board of Directors of RosettaNet, as a Trustee of the W. Edwards Deming Institute, and President of NEDA’s (National Electronic Distribution Association) Education Foundation.

Donald Kennedy, Ph.D., Chairman
Donald Kennedy is President Emeritus and Bing Professor of Environmental Science and Policy, Emeritus at Stanford University. He is also a Senior Fellow of the Freeman-Spogli Institute for International Studies and the Wood Institute for the Environment, and is a member of the Food Security and Environment Program in both Institutes. Dr. Kennedy was editor-in-chief of Science (2000-2008) and also served as Commissioner of the US Food and Drug Administration during the Carter administration. Dr. Kennedy is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. He served on the National Commission for Public Service and the Carnegie Commission on Science, Technology and Government, and is a founding director of the Health Effects Institute. He currently serves as a director of the Carnegie Endowment for International Peace, and as co-chair of the National Academies’ Project on Science, Technology and Law. Dr. Kennedy received A.B. and Ph.D. degrees in biology from Harvard University.

David G. Nathan, M.D.
David Nathan is President Emeritus of Dana-Farber Cancer Institute, which provides patient care in addition to conducting research. He was president of DFCI from 1995 to 2000. Dr. Nathan chaired the Department of Pediatrics and served as physician-in-chief of Children’s Hospital in Boston from 1985 to 1995. He was chief of hematology and oncology at CHB and DFCI after serving as chief of hematology at CHB between 1967 and 1984. Dr. Nathan was senior resident in medicine at the then Peter Bent Brigham Hospital and clinical associate at the National Cancer Institute from 1959 to 1966. His textbook, titled Hematology of Infancy and Childhood, is the leading text in the field. He is the author of two popular books: Genes, Blood and Courage and The Cancer Treatment Revolution: How Smart Drugs and Other New Therapies Are Renewing Our Hope and Changing the Face of Medicine. Dr. Nathan is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Pediatric Society, the Institute of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. He is the recipient of numerous awards, including the National Medal of Science, the Stratton medal of the American Society of Hematology, the Walker Prize of the Boston Museum of Science, the John Howland Medal of the American Pediatric Society, and the George M. Kober Medal of the Association of American Physicians. He is one of only three physicians to receive both the Howland and Kober medals.

John G. Curd, M.D., Consulting Chief Medical Officer
John Curd has been the President and Chief Medical Officer at Threshold Pharmaceuticals since 2007. He had joined Threshold Pharmaceuticals as a member of the management team to lead the clinical development of product development candidates including Threshold's hypoxia activated prodrug, TH-302. Prior to Threshold Pharmaceuticals, Dr. Curd was President and Chief Medical Officer at Novacea, Inc. since 2001. He had served in senior roles at Maxygen and VaxGen, Inc. from June 1999 to December 2001, and Vice President of Clinical Development at Genentech, Inc. from December 1991 to June 1999. While at Genentech, he directed the clinical development of Herceptin®, Rituxan®, Xolair®, and Raptiva®. From 1978 to 1991, Dr. Curd served in various positions including President of the Medical Staff at Scripps Clinical and Research Foundation in La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.